ReNeuron appoints new chief scientific officer
The cell-based therapies developer said Dr Stefano Pluchino will join the company with immediate effect on a part-time basis
Company
ReNeuron Group PLC
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 3 of 15
ReNeuron unveils new collaborations, data findings on exosome technology platform
If the data collected from the new collaborations is positive, the company reckons it could seek potential out-licensing deals in six months or so
ReNeuron Group puts the focus on exosome technology
Reneuron has developed exosomes that can deliver a medically relevant payload of viral vaccines that might help in the fight against coronavirus.
ReNeuron begins search for new chief financial officer
“After twenty years at the company, and with the business now in a much stronger financial position, it is the right time for me to move on to new challenges,” said Michael Hunt
ReNeuron says phase IIa eye disease study "proceeding according to plan" as new group is dosed
Data from the clinical assessment will be presented later this year
ReNeuron jumps as US patent granted for hRPC therapy candidate
hRPC is designed to treat retinitis pigmentosa, an inherited disorder that causes blindness
ReNeuron raising up to £15mln to fund two key R&D programmes
The new investment that will be used to fund an expanded study on its treatment for a degenerative eye disease and to deliver proof-of-concept data from its exosome collaborations
ReNeuron Group says dosing has begun on expanded phase IIa trial of eye disease treatment
Earlier results from the clinical assessment of its hRPC cell therapy for the degenerative eye condition retinitis pigmentosa have been highly encouraging
ReNeuron confirms plan to reduce number of non-executive directors and appoint one from Obotritia Capital
Mark Evans, the chairman of significant ReNeuron shareholder Obotritia, will be appointed as a non-independent non-executive director of the company at the AGM on September 10
ReNeuron says US Patent and Trademark office has issued an allowance for its patent relating to human retinal progenitor cells
This notification of allowance in the US adds further intellectual property protection to the hRPC technology, which already has patent protection in a number of other major territories including Europe, Japan and Australia
ReNeuron up as it highlights significant near term opportunities, reduces full year losses
The biotech said its hRPC stem cell therapy candidate for retinal disease has delivered “positive and sustained top-line efficacy data” in an ongoing US Phase 1/2a clinical trial
ReNeuron treatment for degenerative eye condition “meaningful effect” for all points measured up to 18 months
Chief executive Olav Hellebø said: “The persistence of the observed clinical benefit is particularly encouraging”
ReNeuron Group agrees gene silencing collaboration with “major biotechnology company”
The two companies will use ReNeuron's exosomes technology to deliver the therapeutic
ReNeuron to focus on retinal disease and exosome-based technology programmes
This, chief executive Olav Hellebø said, provided the company “with significant near-term opportunities to deliver value-enhancing data and commercial partnerships”.
ReNeuron Group's CTX therapy shows early promise in treating Huntington's disease
New data items show for the first time that ReNeuron's CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease
ReNeuron jumps as it agrees research deal with unnamed “major pharmaceutical company” to develop emerging cell technology
The focus will be on ReNeuron's exosome technology
ReNeuron assessing potential of emerging cell technology in the coronavirus fight
It has developed a line of the human exosomes that can deliver a medically relevant payload; viral vaccines, for example
ReNeuron encouraged by 12-month data from cell therapy for degenerative eye disease
The update was provided alongside news the group had applied to the US regulator to add a further nine people to its phase I/IIa clinical study
ReNeuron says positive clinical data from Phase 2a trial of its CTX stem cell therapy candidate published in peer-reviewed journal
Data from the PISCES II study were originally presented by Professor Keith Muir at the American Heart Association International Stroke Conference in January 2018
Archive
Proactive news snapshot: ReNeuron, Metal Tiger, i3 Energy, Kodal Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire